Search

Displaying results 8641 - 8650 of 9881 in total
  1. Drug

    Clevidipine

    go.drugbank.com/drugs/DB04920
    ApprovedInvestigational

    Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

  2. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].

  3. Drug

    Orelabrutinib

    go.drugbank.com/drugs/DB16272
    Investigational

    Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).

  4. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered

  5. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.

  6. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    Tebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. … severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary tract infections generally required hospitalization, a

  7. Drug

    Nutlin-3

    go.drugbank.com/drugs/DB17039
    Experimental

    Nutlin-3 is a small molecule inhibitor that targets p53-Mdm2 interaction.[A253057]

  8. Drug

    PHA-767491

    go.drugbank.com/drugs/DB17043
    Investigational

    PHA-767491 is a Cdc7/CDK9 inhibitor.[A253077]

  9. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.

  10. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    Lotilaner is an ectoparasiticide that is a member of the isoxazoline family of compounds.